Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01665794 · ClinicalTrials.gov registry record · Phase 1
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01665794 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 25 participants.
The verdict
NCT01665794, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete. This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.
Interventions
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG Carfilzomib
- DRUG dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-08-13 |
| Est. Completion | 2025-11-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01665794
The ClinicalTrials.gov registry entry for NCT01665794 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Daratumumab is the first listed.
NCT01665794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01665794 about?
NCT01665794 is a clinical study titled "Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma". The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete. This study will also investigate the effects of ad...
What is the current status of trial NCT01665794?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-08-13. Estimated completion is 2025-11-14.
What interventions are being tested in trial NCT01665794?
The interventions under investigation include: Daratumumab (DRUG), Pomalidomide (DRUG), Carfilzomib (DRUG), dexamethasone (DRUG).
Who is sponsoring clinical trial NCT01665794?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.